{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:07:19Z","timestamp":1791518839072,"version":"4.3.4"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2023NSFSC1679"],"award-info":[{"award-number":["2023NSFSC1679"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003661"],"award-info":[{"award-number":["82003661"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2682022KJ042"],"award-info":[{"award-number":["2682022KJ042"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejpb.2023.10.010","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T19:33:51Z","timestamp":1697312031000},"page":"147-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Overcoming delivery barriers for RNA therapeutics in the treatment of rheumatoid arthritis"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0998-7583","authenticated-orcid":false,"given":"Bin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-6478","authenticated-orcid":false,"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.10.010_b0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejpb.2023.10.010_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113834","article-title":"Nucleic acid delivery for therapeutic applications","volume":"178","author":"Gupta","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.10.010_b0015","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0020","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/anie.200504277","article-title":"Colorimetric Screening of DNA-Binding Molecules with Gold Nanoparticle Probes","volume":"45","author":"Han","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejpb.2023.10.010_b0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","article-title":"Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs","volume":"8","author":"Dilliard","year":"2023","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ejpb.2023.10.010_b0030","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/d41573-020-00078-0","article-title":"RNA therapeutics on the rise","volume":"19","author":"Wang","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2023.10.010_b0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2023.10.010_b0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2023.10.010_b0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2023.10.010_b0055","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/cancers14061588","article-title":"Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine","volume":"14","author":"Smith","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejpb.2023.10.010_b0060","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: from concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.ejpb.2023.10.010_b0065","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.3390\/ijms23052736","article-title":"Current Advances in RNA Therapeutics for Human Diseases","volume":"23","author":"Zogg","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.10.010_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.710738","article-title":"RNA Therapeutics - Research and Clinical Advancements","volume":"8","author":"Feng","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejpb.2023.10.010_b0075","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The Pathogenesis of Rheumatoid Arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2023.10.010_b0080","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2023.10.010_b0085","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and Management of Rheumatoid Arthritis: A Review","volume":"320","author":"Aletaha","year":"2018","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejpb.2023.10.010_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejpb.2023.10.010_b0095","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2023.10.010_b0100","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14740338.4.4.637","article-title":"Adalimumab: a review of side effects","volume":"4","author":"Scheinfeld","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ejpb.2023.10.010_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrrheum.2012.176","article-title":"siRNA-based therapeutic approaches for rheumatic diseases","volume":"9","author":"Apparailly","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: First Approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2023.10.010_b0120","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2023.10.010_b0125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2012.12.029","article-title":"Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format","volume":"166","author":"Phua","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.10.010_b0130","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2023.10.010_b0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2023.10.010_b0140","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1093\/nar\/gkaa576","article-title":"A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics","volume":"48","author":"Deprey","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/nat.2017.0716","article-title":"Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs","volume":"28","author":"Johannes","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ejpb.2023.10.010_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106665","article-title":"Endosomal escape of nucleic acids from extracellular vesicles mediates functional therapeutic delivery","volume":"188","author":"Pham","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0155","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00441-016-2563-y","article-title":"Effect of inhibiting MMP13 and ADAMTS5 by intra-articular injection of small interfering RNA in a surgically induced osteoarthritis model of mice","volume":"368","author":"Hoshi","year":"2017","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0160","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/s41551-021-00780-3","article-title":"Amelioration of post-traumatic osteoarthritis via nanoparticle depots delivering small interfering RNA to damaged cartilage","volume":"5","author":"Bedingfield","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ejpb.2023.10.010_b0165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbrc.2022.02.081","article-title":"CD81 inhibition with the cytoplasmic RNA vector producing anti-CD81 antibodies suppresses arthritis in a rat CIA model","volume":"604","author":"Fujii","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejpb.2023.10.010_b0170","doi-asserted-by":"crossref","first-page":"20304","DOI":"10.1021\/acsami.8b22693","article-title":"Role of Liposome Size, Surface Charge, and PEGylation on Rheumatoid Arthritis Targeting Therapy","volume":"11","author":"Ren","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejpb.2023.10.010_b0175","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/11595490-000000000-00000","article-title":"Gene therapy for rheumatoid arthritis: current status and future prospects","volume":"25","author":"Fabre","year":"2011","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejpb.2023.10.010_b0180","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.2147\/IJN.S382252","article-title":"A Multifunctional Nano-Delivery System Against Rheumatoid Arthritis by Combined Phototherapy, Hypoxia-Activated Chemotherapy, and RNA Interference","volume":"17","author":"Li","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2023.10.010_b0185","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1021\/acs.biomac.2c01117","article-title":"Amphiphilic Phosphorus Dendrons Associated with Anti-inflammatory siRNA Reduce Symptoms in Murine Collagen-Induced Arthritis","volume":"24","author":"Yu","year":"2023","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2023.10.010_b0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/jpet.111.185884","article-title":"Arthritic Joint-Targeting Small Interfering RNA-Encapsulated Liposome: Implication for Treatment Strategy for Rheumatoid Arthritis","volume":"340","author":"Komano","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2023.10.010_b0195","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mt.2008.220","article-title":"Chitosan\/siRNA Nanoparticle\u2013mediated TNF-\u03b1 Knockdown in Peritoneal Macrophages for Anti-inflammatory Treatment in a Murine Arthritis Model","volume":"17","author":"Howard","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2023.10.010_b0200","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/art.23660","article-title":"Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes","volume":"58","author":"Khoury","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejpb.2023.10.010_b0205","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.7150\/thno.32268","article-title":"Hybrid micelles containing methotrexate-conjugated polymer and co-loaded with microRNA-124 for rheumatoid arthritis therapy","volume":"9","author":"Hao","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2023.10.010_b0210","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ymthe.2019.05.002","article-title":"Lipidoid-siRNA Nanoparticle-Mediated IL-1\u03b2 Gene Silencing for Systemic Arthritis Therapy in a Mouse Model","volume":"27","author":"Song","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2023.10.010_b0215","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/cei\/uxac116","article-title":"Preparation of mesoporous silica nanocarriers targeting glucose-6-phosphate isomerase inhibition and application in the treatment of rheumatoid arthritis","volume":"211","author":"Zong","year":"2023","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0220","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1172\/JCI75673","article-title":"Peptide-siRNA nanocomplexes targeting NF-\u03baB subunit p65 suppress nascent experimental arthritis","volume":"124","author":"Zhou","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejpb.2023.10.010_b0225","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/nnm.13.217","article-title":"Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis","volume":"9","author":"Duan","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2023.10.010_b0230","doi-asserted-by":"crossref","first-page":"e2202604","DOI":"10.1002\/smll.202202604","article-title":"Radicals Scavenging MOFs Enabling Targeting Delivery of siRNA for Rheumatoid Arthritis Therapy","volume":"18","author":"Guo","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.ejpb.2023.10.010_b0235","doi-asserted-by":"crossref","first-page":"e78619","DOI":"10.1371\/journal.pone.0078619","article-title":"Systemic delivery of small interfering RNA targeting the interleukin-2\/15 receptor \u03b2 chain prevents disease progression in experimental arthritis","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2023.10.010_b0240","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biomaterials.2017.01.008","article-title":"Targeting NF-kB signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for arthritis therapy","volume":"122","author":"Wang","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2023.10.010_b0245","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/mt.2010.27","article-title":"Targeted Delivery of siRNA to Macrophages for Anti-inflammatory Treatment","volume":"18","author":"Kim","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2023.10.010_b0250","article-title":"Efficient Treatment of Rheumatoid Arthritis by Degradable LPCE Nano-Conjugate-Delivered p65 siRNA","volume":"14","author":"Chen","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.10.010_b0255","first-page":"2393","article-title":"An enhanced RRM2 siRNA delivery to rheumatoid arthritis fibroblast-like synoviocytes through a liposome-protamine-DNA-siRNA complex with cell permeable peptides","volume":"42","author":"Wang","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejpb.2023.10.010_b0260","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jconrel.2020.11.041","article-title":"RNA interference-mediated suppression of TNF-\u03b1 converting enzyme as an alternative anti-TNF-\u03b1 therapy for rheumatoid arthritis","volume":"330","author":"Song","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.10.010_b0265","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.4049\/jimmunol.1403012","article-title":"A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA","volume":"194","author":"Mehta","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0270","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2015.08.025","article-title":"Notch1 targeting siRNA delivery nanoparticles for rheumatoid arthritis therapy","volume":"216","author":"Kim","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.10.010_b0275","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.omtn.2022.12.008","article-title":"Chemically modified small interfering RNA targeting Hedgehog signaling pathway for rheumatoid arthritis therapy","volume":"31","author":"Lin","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejpb.2023.10.010_b0280","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/mt.2013.245","article-title":"TNF-\u03b1 Gene Silencing Using Polymerized siRNA\/Thiolated Glycol Chitosan Nanoparticles for Rheumatoid Arthritis","volume":"22","author":"Lee","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2023.10.010_b0285","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1038\/mtna.2016.39","article-title":"Acid-Sensitive Sheddable PEGylated PLGA Nanoparticles Increase the Delivery of TNF-\u03b1 siRNA in Chronic Inflammation Sites","volume":"5","author":"Aldayel","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejpb.2023.10.010_b0290","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jconrel.2022.01.029","article-title":"CaP-based anti-inflammatory HIF-1alpha siRNA-encapsulating nanoparticle for rheumatoid arthritis therapy","volume":"343","author":"Liu","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.10.010_b0295","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/pharmaceutics13040453","article-title":"Carbon Nanotubes\u2014Potent Carriers for Targeted Drug Delivery in Rheumatoid Arthritis","volume":"13","author":"Kofoed Andersen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.10.010_b0300","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/IJN.S146942","article-title":"In vivo therapeutic efficacy of TNF\u03b1 silencing by folate-PEG-chitosan-DEAE\/siRNA nanoparticles in arthritic mice","volume":"13","author":"Shi","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2023.10.010_b0305","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jconrel.2018.05.035","article-title":"Lipid nanoparticles with minimum burst release of TNF-\u03b1 siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate","volume":"283","author":"Aldayel","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.10.010_b0310","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2019.06.009","article-title":"Lipidoid-polymer hybrid nanoparticles loaded with TNF siRNA suppress inflammation after intra-articular administration in a murine experimental arthritis model","volume":"142","author":"Jansen","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.10.010_b0315","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jconrel.2012.05.004","article-title":"MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model","volume":"161","author":"te Boekhorst","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.10.010_b0320","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s13346-021-01037-x","article-title":"Nanomedicine-based combination of dexamethasone palmitate and MCL-1 siRNA for synergistic therapeutic efficacy against rheumatoid arthritis","volume":"11","author":"Li","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0325","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1039\/C9BM01025D","article-title":"Nanoparticle-delivered siRNA targeting Bruton\u2019s tyrosine kinase for rheumatoid arthritis therapy","volume":"7","author":"Zhao","year":"2019","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejpb.2023.10.010_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106933","article-title":"Nanoparticle-facilitated delivery of BAFF-R siRNA for B cell intervention and rheumatoid arthritis therapy","volume":"88","author":"Wu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0335","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.colsurfb.2017.04.023","article-title":"Neutral PEGylated liposomal formulation for efficient folate-mediated delivery of MCL1 siRNA to activated macrophages","volume":"155","author":"Nogueira","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejpb.2023.10.010_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120204","article-title":"PLGA\/PCADK composite microspheres containing hyaluronic acid-chitosan siRNA nanoparticles: A rational design for rheumatoid arthritis therapy","volume":"596","author":"Zhao","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.010_b0345","doi-asserted-by":"crossref","first-page":"2005661","DOI":"10.1002\/smll.202005661","article-title":"Targeted Combination of Antioxidative and Anti-Inflammatory Therapy of Rheumatoid Arthritis using Multifunctional Dendrimer-Entrapped Gold Nanoparticles as a Platform","volume":"16","author":"Li","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.ejpb.2023.10.010_b0350","doi-asserted-by":"crossref","first-page":"2206261","DOI":"10.1002\/adfm.202206261","article-title":"Injectable Amphipathic Artesunate Prodrug-Hydrogel Microsphere as Gene\/Drug Nano-Microplex for Rheumatoid Arthritis Therapy","volume":"32","author":"Li","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ejpb.2023.10.010_b0355","doi-asserted-by":"crossref","first-page":"8546","DOI":"10.1039\/D0NR00454E","article-title":"A novel indomethacin\/methotrexate\/MMP-9 siRNA in situ hydrogel with dual effects of anti-inflammatory activity and reversal of cartilage disruption for the synergistic treatment of rheumatoid arthritis","volume":"12","author":"Yin","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2023.10.010_b0360","doi-asserted-by":"crossref","unstructured":"Chen J, Tan J, Li J, Cheng W, Ke L, Wang A, et al. Genetically Engineered Biomimetic Nanoparticles for Targeted Delivery of mRNA to Treat Rheumatoid Arthritis. Small Methods n.d.;n\/a:2300678. https:\/\/doi.org\/10.1002\/smtd.202300678.","DOI":"10.1002\/smtd.202300678"},{"key":"10.1016\/j.ejpb.2023.10.010_b0365","unstructured":"Cationic liposome-mediated RNA transfection. | PNAS n.d. https:\/\/www.pnas.org\/doi\/abs\/10.1073\/pnas.86.16.6077 (accessed August 3, 2023)."},{"key":"10.1016\/j.ejpb.2023.10.010_b0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ejpb.2023.10.010_b0375","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3390\/molecules22101724","article-title":"Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation","volume":"22","author":"Sun","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2023.10.010_b0380","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1021\/acsabm.1c01205","article-title":"Nucleic Acids for Potential Treatment of Rheumatoid Arthritis","volume":"5","author":"Sun","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.ejpb.2023.10.010_b0385","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11095-018-2401-x","article-title":"Notch-1 siRNA and Methotrexate towards a Multifunctional Approach in Rhematoid Arthritis Management: a Nanomedicine Approach","volume":"35","author":"Zhao","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0390","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1093\/nar\/gks463","article-title":"Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes","volume":"40","author":"Wahlgren","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0395","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.4049\/jimmunol.1800304","article-title":"Therapeutic Potential of Mesenchymal Cell-Derived miRNA-150-5p-Expressing Exosomes in Rheumatoid Arthritis Mediated by the Modulation of MMP14 and VEGF","volume":"201","author":"Chen","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0400","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/pharmaceutics15020598","article-title":"Exosome-Based Carrier for RNA Delivery: Progress and Challenges","volume":"15","author":"Lu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.10.010_b0405","first-page":"1","article-title":"Exosome-based small RNA delivery: Progress and prospects","volume":"13","author":"Lu","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.10.010_b0410","doi-asserted-by":"crossref","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ejpb.2023.10.010_b0415","doi-asserted-by":"crossref","first-page":"13698","DOI":"10.1039\/C5RA26563K","article-title":"The evaluation of cellular uptake efficiency and tumor-targeting ability of MPEG\u2013PDLLA micelles: effect of particle size","volume":"6","author":"Hao","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2023.10.010_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2019.07.002","article-title":"Applications of RNA interference in the treatment of arthritis","volume":"214","author":"Rai","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0425","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.4049\/jimmunol.1403012","article-title":"A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA","volume":"194","author":"Mehta","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0430","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2217\/nnm.11.90","article-title":"Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model","volume":"6","author":"Scheinman","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2023.10.010_b0435","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/mt.2010.27","article-title":"Targeted Delivery of siRNA to Macrophages for Anti-inflammatory Treatment","volume":"18","author":"Kim","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2023.10.010_b0440","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1042\/BJ20110352","article-title":"Glucan particles for selective delivery of siRNA to phagocytic cells in mice","volume":"436","author":"Tesz","year":"2011","journal-title":"Biochem. J"},{"key":"10.1016\/j.ejpb.2023.10.010_b0445","doi-asserted-by":"crossref","unstructured":"Jessica Wahlgren, Tanya De L. Karlson, Mikael Brisslert, Forugh Vaziri Sani, Esbj\u00f6rn Telemo, Per Sunnerhagen, et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res. 40 (2012) e130. https:\/\/doi.org\/10.1093\/nar\/gks463.","DOI":"10.1093\/nar\/gks463"},{"key":"10.1016\/j.ejpb.2023.10.010_b0450","article-title":"Metabolically engineered stem cell\u2013derived exosomes to regulate macrophage heterogeneity in rheumatoid arthritis. Science","author":"You","year":"202170083","journal-title":"Advances"},{"key":"10.1016\/j.ejpb.2023.10.010_b0455","unstructured":"Small but mighty: transforming immuno-oncology and RNA medicine with the power of nanobiotechnology n.d."},{"key":"10.1016\/j.ejpb.2023.10.010_b0460","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0465","doi-asserted-by":"crossref","unstructured":"Qin Shi, Elsa-Patricia Rondon-Cavanzo, Isadora Pfeifer Dalla Picola, Marcio Jos\u00e9 Tiera, Xiaoling Zhang, Kerong Dai, et al. In vivo therapeutic efficacy of TNFα silencing by folate-PEG-chitosan-DEAE\/siRNA nanoparticles in arthritic mice, IJN 13 (2018) 387\u2013402. https:\/\/doi.org\/10.2147\/IJN.S146942.","DOI":"10.2147\/IJN.S146942"},{"key":"10.1016\/j.ejpb.2023.10.010_b0470","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/ar7000815","article-title":"Discovery and Development of Folic-Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and Inflammatory Diseases","volume":"41","author":"Low","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0475","doi-asserted-by":"crossref","unstructured":"Xiangshi Sun, Shiyan Dong, Xiangyu Li, Kongtong Yu, Fengying Sun, Robert J. Lee, et al. Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy, Nanomed.: Nanotechnol., Biol. Med. 20 (2019) 102017. https:\/\/doi.org\/10.1016\/j.nano.2019.102017.","DOI":"10.1016\/j.nano.2019.102017"},{"key":"10.1016\/j.ejpb.2023.10.010_b0480","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.2147\/IJN.S382252","article-title":"A Multifunctional Nano-Delivery System Against Rheumatoid Arthritis by Combined Phototherapy, Hypoxia-Activated Chemotherapy, and RNA Interference","volume":"17","author":"Li","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2023.10.010_b0485","series-title":"Particulate Products: Tailoring Properties for Optimal Performance","first-page":"323","article-title":"The Role of Particle Size in Drug Release and Absorption","author":"Giuseppina Sandri","year":"2014"},{"key":"10.1016\/j.ejpb.2023.10.010_b0490","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12918-017-0491-4","article-title":"A multiscale modeling study of particle size effects on the tissue penetration efficacy of drug-delivery nanoparticles","volume":"11","author":"Islam","year":"2017","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0495","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12943-017-0683-y","article-title":"Nano-based delivery of RNAi in cancer therapy","volume":"16","author":"Xin","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejpb.2023.10.010_b0500","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11095-006-9146-7","article-title":"Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications","volume":"24","author":"Shekunov","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0505","unstructured":"Physical Properties of Nanoparticles That Result in Improved Cancer Targeting n.d. https:\/\/www.hindawi.com\/journals\/jo\/2020\/5194780\/ (accessed July 14, 2023)."},{"key":"10.1016\/j.ejpb.2023.10.010_b0510","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1093\/nar\/gkl941","article-title":"Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect","volume":"34","author":"Veldhoen","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0515","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1021\/nn202597c","article-title":"Chimeric Capsid Protein as a Nanocarrier for siRNA Delivery: Stability and Cellular Uptake of Encapsulated siRNA","volume":"5","author":"Choi","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2023.10.010_b0520","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1124\/jpet.111.180042","article-title":"Therapeutic Effects on Atopic Dermatitis by Anti-RelA Short Interfering RNA Combined with Functional Peptides Tat and AT1002","volume":"338","author":"Uchida","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2023.10.010_b0525","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.10.010_b0530","first-page":"606","article-title":"Highly Stable RNA Capture by Dense Cationic Polymer Brushes for the Design of Cytocompatible","volume":"19","author":"Li","year":"2018","journal-title":"Serum-Stable SiRNA Delivery Vectors. Biomacromolecules"},{"key":"10.1016\/j.ejpb.2023.10.010_b0535","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1002\/cncr.25321","article-title":"Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells","volume":"116","author":"Abbasi","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2023.10.010_b0540","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jconrel.2022.01.029","article-title":"CaP-based anti-inflammatory HIF-1\u03b1 siRNA-encapsulating nanoparticle for rheumatoid arthritis therapy","volume":"343","author":"Liu","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.10.010_b0545","series-title":"Antiviral RNAi: Concepts, Methods, and Applications","first-page":"77","article-title":"Chemical Modification of Small Interfering RNA","author":"Bramsen","year":"2011"},{"key":"10.1016\/j.ejpb.2023.10.010_b0550","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1172\/JCI33483","article-title":"Chemical modification: the key to clinical application of RNA interference?","volume":"117","author":"Corey","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejpb.2023.10.010_b0555","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/cbic.202000009","article-title":"Developments in siRNA Modification and Ligand Conjugated Delivery To Enhance RNA Interference Ability","volume":"21","author":"Maguregui","year":"2020","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejpb.2023.10.010_b0560","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.addr.2020.10.014","article-title":"Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing","volume":"168","author":"Chen","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.10.010_b0565","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.omtn.2022.12.008","article-title":"Chemically modified small interfering RNA targeting Hedgehog signaling pathway for rheumatoid arthritis therapy","volume":"31","author":"Lin","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejpb.2023.10.010_b0570","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle\u2013mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0575","doi-asserted-by":"crossref","first-page":"e1530","DOI":"10.1002\/wnan.1530","article-title":"Nanoscale platforms for messenger RNA delivery","volume":"11","author":"Li","year":"2019","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2023.10.010_b0580","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.addr.2009.04.005","article-title":"Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape","volume":"61","author":"Endoh","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.10.010_b0585","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/adfm.200801795","article-title":"Biodegradable Dextran Nanogels for RNA Interference: Focusing on Endosomal Escape and Intracellular siRNA Delivery","volume":"19","author":"Raemdonck","year":"2009","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ejpb.2023.10.010_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115047","article-title":"Get out or die trying: Peptide- and protein-based endosomal escape of RNA therapeutics","volume":"200","author":"Klipp","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.10.010_b0595","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1021\/ar3000162","article-title":"Nucleic Acid Delivery: The Missing Pieces of the Puzzle?","volume":"45","author":"Nguyen","year":"2012","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejpb.2023.10.010_b0600","doi-asserted-by":"crossref","first-page":"9926","DOI":"10.1021\/jacs.2c02706","article-title":"Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment","volume":"144","author":"Xue","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2023.10.010_b0605","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215711120","article-title":"In vivo bone marrow microenvironment siRNA delivery using lipid\u2013polymer nanoparticles for multiple myeloma therapy","volume":"120","author":"Guimar\u00e3es","year":"2023","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123002709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123002709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:54:24Z","timestamp":1760547264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123002709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":121,"alternative-id":["S0939641123002709"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.10.010","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming delivery barriers for RNA therapeutics in the treatment of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}